Baudax Bio (NASDAQ:BXRX – Get Rating) is scheduled to be releasing its earnings data before the market opens on Thursday, May 5th. Analysts expect Baudax Bio to post earnings of ($1.85) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.
Baudax Bio (NASDAQ:BXRX – Get Rating) last posted its quarterly earnings results on Wednesday, March 16th. The company reported $10.03 EPS for the quarter, topping analysts’ consensus estimates of ($5.25) by $15.28. On average, analysts expect Baudax Bio to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of BXRX traded up $0.01 during trading hours on Tuesday, reaching $1.63. The stock had a trading volume of 193 shares, compared to its average volume of 134,706. Baudax Bio has a 12 month low of $1.38 and a 12 month high of $40.60. The stock has a market capitalization of $10.45 million, a PE ratio of -0.12 and a beta of 2.02. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.18 and a current ratio of 1.50. The company’s 50-day moving average is $1.86 and its two-hundred day moving average is $1.02.
Several hedge funds have recently made changes to their positions in the company. Morgan Stanley raised its position in shares of Baudax Bio by 13,944.1% during the second quarter. Morgan Stanley now owns 362,339 shares of the company’s stock worth $276,000 after purchasing an additional 359,759 shares during the period. Millennium Management LLC raised its holdings in shares of Baudax Bio by 454.3% in the 3rd quarter. Millennium Management LLC now owns 326,602 shares of the company’s stock worth $184,000 after acquiring an additional 267,682 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Baudax Bio by 27.3% during the third quarter. Geode Capital Management LLC now owns 680,742 shares of the company’s stock valued at $383,000 after purchasing an additional 145,950 shares in the last quarter. UBS Group AG bought a new position in shares of Baudax Bio during the third quarter valued at about $36,000. Finally, Virtu Financial LLC lifted its position in shares of Baudax Bio by 37.5% during the fourth quarter. Virtu Financial LLC now owns 170,454 shares of the company’s stock valued at $37,000 after purchasing an additional 46,444 shares in the last quarter.
About Baudax Bio (Get Rating)
Baudax Bio, Inc, a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine, which is under phase II clinical trial.
- Get a free copy of the StockNews.com research report on Baudax Bio (BXRX)
- Another Buy The Dip Opportunity In Freshpet
- Inflation Wreaks Havoc On Haverty Furniture Company
- Tractor Supply Stock Should Plow Ahead
- MarketBeat Podcast: Investing In Innovation, Robotics, AI and Healthcare
- It’s Time to Book an Appointment for Teladoc Stock
Receive News & Ratings for Baudax Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baudax Bio and related companies with MarketBeat.com's FREE daily email newsletter.